

Atara Biotherapeutics, Inc.  
Form 8-K  
February 10, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 6, 2017**

**Atara Biotherapeutics, Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-36548**  
**(Commission**  
  
**File Number)**

**46-0920988**  
**(IRS Employer**  
  
**Identification No.)**

**701 Gateway Boulevard, Suite 200**

**South San Francisco, CA**  
**(Address of Principal Executive Offices)**

**94080**  
**(Zip Code)**

**Registrant's Telephone Number, Including Area Code: (415) 287-2410**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 6, 2017, the Compensation Committee (the *Committee*) of the Board of Directors of Atara Biotherapeutics, Inc. (the *Company*) approved discretionary cash bonus payments to its principal executive officer and named executive officers in recognition of the Company's performance during 2016 as set forth in the table below:

<b>Name</b>	<b>Title</b>	<b>Bonus</b>
Isaac Ciechanover	Chief Executive Officer	\$ 270,270
Christopher Haqq	Executive Vice President, Chief Scientific Officer	\$ 154,752
Heather Turner	Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy	\$ 127,592

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Atara Biotherapeutics, Inc.**

By: /s/ John McGrath  
John McGrath

Chief Financial Officer

Date: February 10, 2017